Morgan Stanley Changes Ratings on RCUS, NRIX, IOBT
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.
Nurix Therapeutics presented positive Phase 1 data for its BTK degrader, bexobrutideg (NX-5948), showing high response rates and favorable safety in heavily pre-treated Waldenström Macroglobulinemia patients.